Last quarter, a top-20 pharma company pulled biostatistics, data management, and pharmacovigilance out of a $400 million full-service CRO model. Kept the CRO for site management and recruitment infrastructure. Hired an FSP provider for everything else.
The CRO’s stock dropped 3% on the earnings call when the CEO mentioned ‘evolving client preferences.’ That’s Wall Street code for: our customers are leaving, one function at a time.
This isn’t an anomaly. 70% of large pharma is increasing FSP work. Not maintaining. Increasing. The full-service model that built the CRO industry is being dismantled — not by regulators, not by technology, but by sponsors who got tired of paying for coordination that never materialized.
The Integration Tax
Full-service CRO contracts sell one thing above all else: integration. One vendor, one contract, one point of accountability. Functions that talk to each other. Data that flows without manual handoffs.
That’s what the proposal says. Here’s what actually happens.
The biostatisticians sit in Bangalore. The data managers sit in Krakow. The clinical operations team sits in North Carolina. They use different systems. They report to different functional heads. The ‘integration’ is a weekly status call where each function reads its slides and nobody asks hard questions.
Sponsors still spend 30-40% of their outsourcing management bandwidth coordinating functions that are supposedly already coordinated. That’s not outsourcing. That’s paying a premium for fragmented delivery wrapped in a unified invoice.
The integration tax — the markup sponsors pay for coordination that happens in the contract but not in practice — runs 15-25% above what the same work costs through an FSP model. On a $200 million program, that’s $30 to $50 million for a coordination layer that mostly produces status reports.
Why FSP Is Winning — and Where It Isn’t
Three shifts made FSP viable for functions that used to require full-service scale.
First, sponsors got good at clinical operations. The VP of Clinical Operations at a mid-size biotech in 2026 has 15 years of CRO management experience. They don’t need a CRO project manager to manage the CRO’s own functions. They need skilled people who plug into their systems and follow their processes. FSP delivers that.
Second, FSP runs 15-25% cheaper per FTE than full-service equivalents. Strip out the overhead layers — the CRO project manager, the functional leads, the governance structure — and the cost per deliverable drops. The savings aren’t theoretical. They show up in the first quarter.
Third — and this is the piece most analyses miss — data ownership changed the economics permanently. AI and predictive analytics need your operational data in your platform. Not locked in a CRO’s proprietary system behind an export fee. Every month your trial data sits in a CRO’s CTMS is a month you can’t train your enrollment prediction models. Sponsors running FSP own their data from day one.
But FSP has blind spots. Site network access? CROs built those relationships over decades. Global regulatory filings across 40 countries? That’s a scale game. Patient recruitment infrastructure with established vendor networks? FSP providers don’t have it.
The sponsors getting this right aren’t choosing FSP or full-service. They’re running hybrid models — FSP for functions where control and data ownership matter, full-service where CRO scale genuinely wins. The ones getting it wrong are the ones treating this as an ideology instead of an engineering decision.
The Uncomfortable Conversation Nobody at Your CRO Wants to Have
If you’re running a clinical program through a full-service CRO right now, ask your outsourcing team three questions.
How much of your outsourcing management bandwidth goes to coordinating functions within your CRO — work that the ‘integration’ should be handling? If the answer is more than 10%, you’re paying the integration tax.
Can you access your raw trial data — not summary reports, raw data — in your own analytics environment within 48 hours? If the answer involves an export request and a change order, your CRO owns your competitive intelligence.
What would it cost to pull biostatistics and data management into an FSP model while keeping the CRO for site management? If nobody on your team has modeled that, you’re running on institutional inertia, not strategy.
Your CRO doesn’t want you to ask these questions. Their business model depends on you not asking them. But in 2026, every dollar of that integration tax is a dollar not going into your pipeline. And your pipeline is what the board cares about.
